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Inmammalian cells, glycogen synthase kinase-3
(GSK-3) exists as two homologs, GSK-3a and
GSK-3b, encoded by independent genes,
which share similar kinase domains but differ
substantially in their termini. Here, we describe
the generation of an allelic series of mouse em-
bryonic stem cell (ESC) lines with 0–4 functional
GSK-3 alleles and examine GSK-3-isoform
function in Wnt/b-catenin signaling. No com-
pensatory upregulation in GSK-3 protein levels
or activity was detected in cells lacking either
GSK-3a or GSK-3b, and Wnt/b-catenin signal-
ing was normal. Only in cells lacking three or
all four of the alleles was a gene-dosage ef-
fect on b-catenin/TCF-mediated transcription
observed. Indeed, GSK-3a/b double-knockout
ESCs displayed hyperactivated Wnt/b-catenin
signaling and were severely compromised in
their ability to differentiate, but could be res-
cued to normality by re-expression of functional
GSK-3. The rheostatic regulation of GSK-3
highlights the importance of considering the
contributions of both homologs when studying
GSK-3 functions in mammalian systems.
INTRODUCTION
Glycogen synthase kinase-3 (GSK-3) is a widely ex-
pressed and highly conserved serine/threonine protein
kinase that is encoded by two genes in mammals, gener-
ating two related protein homologs termed GSK-3a and
GSK-3b (Doble and Woodgett, 2003; Frame and Cohen,
2001). GSK-3a and GSK-3b have almost identical central
kinase domains, but they differ substantially in their
termini. GSK-3a, at 52 kDa, is 5 kDa larger than GSK-3b
due to an amino-terminal, glycine-rich extension of un-
known function (Woodgett, 1990). GSK-3was first isolated
via its activity toward glycogen synthase, the rate-limitingDeveloenzyme of glycogen synthesis (Embi et al., 1980). How-
ever, it has since been shown to play far broader roles in
many cellular processes (Doble and Woodgett, 2003).
The protein kinase is unusual in that it is typically highly
active in resting cells, but is regulated by inhibition in re-
sponse to cellular signals. Such signals include hormone
and growth-factor activation of receptor-tyrosine kinases
that couple to the phosphatidylinositol 30 kinase pathway,
leading to the activation of protein kinase B (PKB/Akt)
(Mitsiades et al., 2004). PKB phosphorylates and inacti-
vates GSK-3a and GSK-3b, and this mechanism contrib-
utes to insulin-induced stimulation of glycogen deposition
by interfering with the negative regulation of glycogen
synthase by GSK-3 (Frame and Cohen, 2001).
GSK-3 is also a key component of the Wnt-signaling
pathway (Doble and Woodgett, 2003). In resting cells,
a fraction of GSK-3 is associated with the Axin-scaffolding
protein, which also binds b-catenin and adenomatous
polyposis coli (APC) (Salahshor and Woodgett, 2005).
GSK-3-mediated phosphorylation of 3 residues on
b-catenin targets it for ubiquitination and subsequent pro-
teosome-mediated degradation (Amit et al., 2002; Liu
et al., 2002). Under such conditions, cytoplasmic levels
of b-catenin are kept at low levels. After engagement of
the Frizzled and LRP5/6 coreceptors by certain members
of the family ofWnt ligands,GSK-3 phosphorylates LRP5/6,
which results in recruitment of the Axin complex to this
coreceptor and leads to decreased phosphorylation of the
GSK-3 sites on b-catenin, allowing themolecule to escape
degradation (Zeng et al., 2005). The resultant accumu-
lated cytoplasmic b-catenin translocates to the nucleus,
where, in association with members of the LEF/TCF family
of DNA-binding proteins, it induces transcription of a se-
ries of target genes that, in a cell-context-dependent man-
ner, promote cell fate and behavioral changes (van Noort
and Clevers, 2002). Several target genes for LEF/TCF
have been identified, including axin2, the protein product
of which is thought to function as a negative-feedback
regulator of Wnt signaling (Jho et al., 2002; Leung et al.,
2002; Lustig et al., 2002).
Since the precise role of GSK-3a andGSK-3b in this and
other cellular processes is poorly understood, we have
taken a gene-targeting approach to investigate thepmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc. 957
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terized mice lacking GSK-3b (Hoeflich et al., 2000). These
mice die late in gestation due to liver apoptosis. The late
onset of the phenotype suggested that, inmouse develop-
ment at least, GSK-3awas largely capable of compensat-
ing for the absence of GSK-3b.
Most inhibitors of GSK-3 cannot discriminate between
GSK-3a and GSK-3b based on their ATP-competitive
mode of action (Meijer et al., 2004). Thus, they are only
useful in providing a way to assess the function of total
cellular GSK-3 activity. Moreover, GSK-3 inhibitors are
prone to nonspecific ‘‘off-target’’ effects that become
more pronounced as the working concentration of inhibi-
tor increases (Bain et al., 2003). A particular GSK-3 inhib-
itor, 6-bromoindirubin-30-oxime (BIO), has been reported
to maintain the pluripotency of mouse and human ESCs
through the activation Wnt/b-catenin signaling (Sato
et al., 2004). Whether BIO’s effects were due solely to its
effects on GSK-3 could not be determined.
Here, we report the generation of embryonic stem cells
engineered to lack various combinations of the GSK-3
alleles. These cells have allowed for a rigorous analysis of
the effect of gene dosage on the properties of the stem
cells and the importance of the two genes inWnt signaling.
RESULTS
Wnt Signaling in GSK-3 Knockout Embryonic
Stem Cell Lines
Usingsequential stepsofgene targetingandG418-induced
gene conversion followed by Cre recombinase-mediated,
site-specific gene deletion, we generated five lines of
mouse embryonic stem cells (ESCs) with graded levels of
GSK-3 expression to examine the extent of functional
redundancy between the two GSK-3 homologs (Figure 1).
All of the cell lines generated were viable and had
growth rates equivalent to wild-type (WT) cells. Immuno-
blotting with an antibody that recognized both GSK-3a
and GSK-3b confirmed that the targeting strategies were
effective in knocking out expression of either protein,
and that the conditionally targeted cells (GSK-3a(flx/flx)) ex-Developressed WT levels of GSK-3a and GSK-3b (Figure 1G).
Quantitation of the relative amounts of GSK-3a and
GSK-3b in total cell lysates of WT ESCs (Figure 1H; see
Figure S1 in the Supplemental Data available with this
article online) revealed that there was no significant differ-
ence between densitometric density of the higher molec-
ular weight band (GSK-3a) containing 52% of the total
complement of GSK-3 and the lower band containing
48% (ANOVA with Tukey’s post-hoc test). Deletion of
a single GSK-3 isoform did not result in a compensatory
increase of the remaining gene product, and, as expected,
there were no GSK-3 bands detectable in the DKO cell
lysates when using the GSK-3a/GSK-3b antibody.
Interestingly, cells lacking GSK-3a appear to contain
less GSK-3b than WT cells (42% versus 48%, respec-
tively; p < 0.05, ANOVA with Tukey’s post-hoc test). We
believe that this is due to comigration of truncated forms
of GSK-3a with GSK-3b that inflate the density of the
‘‘GSK-3b’’ band in immunoblots of WT lysates. The pres-
ence of these truncatedGSK-3a bands is clearly observed
in intermediate or long exposures of immunoblots of
lysates from GSK-3b(/) cells (Figure S1). We quantitated
these lower-molecular weight GSK-3a bands in lysates
fromGSK-3b(/) and determined that their density equals
8% of the total band density measured in WT ESCs. The
sum of the densitometric values of the GSK-3 bands in the
a(/) and b(/) cells (including the lower-molecular
weight GSK-3a bands) was calculated to total 103%.
Statistical analyses revealed no significant difference
between this amount and the sum of the GSK-3 band den-
sities in WT cells (ANOVA with Tukey’s post-hoc test).
Since GSK-3 protein levels might not correlate directly
with kinase activities in the knockout cells, we assayed
the GSK-3 kinase activity in WT and knockout cell lines.
To do this, we partially purified GSK-3 from cell lysates
by using ion-exchange chromatography and assayed for
GSK-3 activity in the purified fractions by using an in vitro
kinase assay. As a consequence of our GSK-3 purification
strategy, a significant proportion of GSK-3a, relative
to GSK-3b, was lost based on postpurification assess-
ment of GSK-3 content by immunoblotting (see inset inFigure 1. Strategy Used to Create Compound Knockouts of GSK-3a and GSK-3b in ES Cells
(A) Targeting strategy for GSK-3a. After homologous recombination with the targeting vector, exon 2 was replacedwith a LoxP-flanked (floxxed) exon
2 and FRT-flanked (flrted) neomycin-resistance cassette. B, BamHI; A, ApaI.
(B) Targeting strategy for GSK-3b. After homologous recombination, exon 2 was replaced with a neomycin-resistance cassette and a single FRT site.
B, BglII.
(C) Overview of the steps required to generate the various ESC lines used in this study (bold type).
(D) Multiplex PCR analysis used to screen ESC clones for G418-mediated conversion from the GSK-3a(+/flx) to theGSK-3a(flx/flx) genotype (steps 1 and
2 in [C]).
(E) PCR analysis used to screen ESC clones for G418-mediated conversion from the GSK-3a(flx/flx);GSK-3b(+/) to the GSK-3a(flx/flx);GSK-3b(/)
genotype (steps 4b–5 in [C]). The white arrowhead indicates a nonspecific band. In (A)–(E), ovals represent FRT recombination sites, triangles
represent LoxP recombination sites, and asterisks represent hybridization sites for Southern blot probes.
(F) Southern blots confirming proper targeting of GSK-3 loci.
(G) WT, GSK-3a(flx/flx), GSK-3a(/), and GSK-3b(/) ESCs all display the same level of cytosolic (first four lanes) and membrane-associated (pellet;
last four lanes) b-catenin. Two different exposures of the same b-catenin immunoblots are presented.
(H) Quantitation of GSK-3 in WT and knockout cell lines. Three lysates, each from a different plate of cells, were analyzed per cell type. Error bars =
SEM. *p < 0.05 (ANOVA with Tukey’s post-hoc test).
(I) Consequence of reduced GSK-3-gene dosage on kinase activity. Each bar represents the average from two independent kinase assay experi-
ments; each assay was performed in triplicate. Error bars = SEM. Inset, immunoblot of the GSK-3-band profiles in the eluates used in the kinase
assays (normalized to total protein content).pmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc. 959
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normalize for this loss (Figure 1I). No compensatory upre-
gulation in kinase activity was observed in any of the
knockout cell types, with the observed kinase activities
mirroring that which would be expected based on the
reduced GSK-3 protein content in the knockout cell lines.
GSK-3 directly phosphorylates the transcriptional regu-
lator b-catenin, marking it for proteosomal degradation
(Liu et al., 2002). Interestingly, we observed no changes
in cytosolic or membrane-associated b-catenin levels in
either of the single-knockout lines (Figure 1G), revealing
a clear redundancy of GSK-3-isoform function with re-
spect to b-catenin phosphorylation. Only when the total
complement of GSK-3 in the ESCs was reduced to one-
quarter of normal levels (‘‘3/4KO’’ cells) did the cytosolic
b-catenin levels begin to increase above levels observed
in WT lysates (Figure 2A). By contrast, the DKO cells
exhibited a massive increase in cytosolic b-catenin levels
(Figure 2A). Overexpression of b-catenin in fibroblasts and
epithelial cell lines has been reported to lead to reduced
cell viability (Kim et al., 2000). However, we found no
evidence of decreased growth in the DKO ESCs. Our
data are consistent with those from ApcMin/Min mouse
ESCs, which are also viable despite their highly elevated
b-catenin levels (Kielman et al., 2002).
To assess whether the observed changes in cytosolic
levels of b-catenin correlated with functional changes in
b-catenin activity in the nucleus, we used a luciferase-
based reporter system to measure TCF-mediated tran-
scription (Figure 2B). TCF-reporter activity was assessed
after treatments with or without Wnt-3a-conditioned
medium for 24 hr. Untreated WT, GSK-3a(/), and GSK-
3b(/) cells showed the same basal levels of TCF-reporter
activity, and all responded to the Wnt-3a treatment to
a similar extent. Interestingly, in the 3/4KO cells, the basal
TCF-reporter activity in the absence of Wnt-3a was signif-
icantly higher than the Wnt-3a-stimulated levels of the WT
and single-knockout cells (p < 0.05). Wnt-3a treatment
further increased the TCF-reporter activity in the 3/4KO
cells (p < 0.001). However, in the DKO cells, Wnt signaling
is completely uncoupled, resulting in a dramatic increase
in TCF-reporter activity.
To determine the functional consequence of GSK-3
gene-dosage manipulation on endogenous target genes,
we extended our findings to a known TCF target gene,
axin2 (Jho et al., 2002; Leung et al., 2002; Lustig et al.,
2002). We used quantitative RT-PCR to determine the
levels of axin2 gene expression in the series of knockout
cells. The pattern of axin2 expression was in agreement
with our TCF-reporter data, with WT and single-knockout
ESC lines having similar low levels of axin2 expression,
3/4KO cells beginning to showaccumulation of axin2mes-
sage beyond baseline levels, and DKO cells expressing
ten timesmore axin2 transcripts thanWT cells (Figure 2C).
We interpret these data to indicate that, in 3/4KO cells,
GSK-3 becomes limiting for Wnt signaling; i.e., a single
GSK-3allele generates insufficientGSK-3 protein to occupy
all b-catenin-destruction complexes in the cell, allowing
some b-catenin to escape phosphorylation-dependent960 Developmental Cell 12, 957–971, June 2007 ª2007 ElseviFigure 2. Consequences of Reduced GSK-3-Gene Dosage
with Respect to Cytosolic b-Catenin Levels and b-Catenin
TCF-Transactivation Activity
(A) Immunoblot analysis of cytosolic GSK-3, b-catenin, and GAPDH
levels. Results from three independent clones with DKO or 3/4KO
genotypes are presented.
(B) TCF-reporter assay. Each bar represents the average from four
independent samples. Error bars = SEM. *p < 0.05; **p < 0.001 (ANOVA
with Newman-Keuls post-hoc test).
(C) Quantitative RT-PCR analysis of Axin2 transcript levels in WT and
GSK-3 knockout ESCs. Error bars = SEM.
(D) Immunofluorescence analysis of a WT and DKO ESC clone stained
for b-catenin and DAPI (nuclei). The scale bars are 10 mm.er Inc.
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complexes with GSK-3 present promotes b-catenin phos-
phorylation and degradation until disrupted byWnt signal-
ing. When GSK-3 is totally absent (DKO), there are no
functional destruction complexes, and cytosolic and nu-
clear b-catenin reach very high levels (Figures 2A and
2B). These levels of cytosolic and nuclear b-catenin are
also clearly observed through immunofluorescence visu-
alization in DKO cells (Figure 2D) and are similar to cells
mutant for APC (Kielman et al., 2002).
Validation of b-Catenin as a GSK-3 Target
Phosphorylation of b-catenin byGSK-3 on residues 33, 37,
and41hasbeenwell documented (Amit et al., 2002;Hagen
et al., 2002;Liu et al., 2002;Salic et al., 2000). Still, as Frame
and Cohen outlined in their seven criteria for establishing
a protein as a bona fide physiological substrate of GSK-3
(Frame and Cohen, 2001), one of the burdens of proof re-
quired for substrate validation is to show that the substrate
cannot be phosphorylated on putative target residues in
cells lacking GSK-3. Using commercially available phos-
pho-specific antibodies for b-catenin, we tested whether
GSK-3 was the only kinase that phosphorylated residues
33, 37, and 41 under ‘‘resting’’ and Wnt-3a-stimulated
conditions in mouse ESCs. As expected, the antibody de-
tected phosphorylated b-catenin species in untreated WT
cells (Figure 3A), a signal that completely disappeared after
30 min of Wnt-3a stimulation. However, in the DKO cells,
this band was completely absent in lysates from both un-
treated and Wnt-3a-treated cells, validating residues 33,
37, and 41 of b-catenin as specific GSK-3 target sites. Ser-
ine 45 (S45) of b-catenin is phosphorylated by CKIa, which
primes b-catenin for subsequent phosphorylation at sites
33, 37, and 41 by GSK-3 (Amit et al., 2002; Zeng et al.,
2005). Phosphorylation of S45 has been suggested to be
the switch that regulates b-catenin phosphorylation and
subsequent degradation (Amit et al., 2002). Using an anti-
body that recognizes b-catenin phosphorylated on either
T41 and/or S45, we found that a 30 min treatment of cells
with Wnt-3a caused a decrease in phosphorylation in WT
cells, but had no effect in DKO cells (Figure 3A). The de-
crease seen with the T41/S45 phospho-specific antibody
in WT cells is most likely due to T41 dephosphorylation
alone, indicating that the level of S45 phosphorylation is
not regulated in response to Wnt. Axin2 serves as a nega-
tive-feedback regulator of canonical Wnt signaling (Jho
et al., 2002; Leung et al., 2002; Lustig et al., 2002). Long-
term treatment (overnight) with Wnt3a, or tonic b-catenin
signaling as observed in DKO cells, would be expected to
cause increases in axin2 protein levels. We observed that
cytosolic levels of Axin2 paralleled changes in cytosolic
b-catenin levels in cells with graded levels of GSK-3 in
response to a 20 hr Wnt-3a treatment (Figure 3B). Similar
changes were observed with the levels of APC protein,
compared with Axin2, in response to Wnt and the graded
levels of GSK-3. This does not appear to be due to
increased transcription ofAPCbecausewe foundnodiffer-
ences of APC transcripts byRT-PCR (data not shown). Our
data are consistent with Choi et al.’s observation ofDeveloincreased APC accumulation without detectable changes
in transcript levels upon Wnt treatment of HEK293 cells
(Choi et al., 2004). Choi et al. provide evidence for the
posttranslational regulation of APC through ubiquitination
and proteasomal degradation in a manner analogous to
b-catenin regulation. Based on overexpression of kinase-
deadGSK-3 and treatment of cellswith theGSK-3 inhibitor
lithium, these authors excluded apossible role forGSK-3 in
the Wnt-mediated stabilization of APC. However, our data
suggest thatGSK-3 is indeed a key regulator of APCstabil-
ity since DKO cells harbor APC levels that are even higher
than those observed with long-term Wnt treatment of
WT cells (Figure 3B).
Rescue of Wnt Signaling by Reintroduction of GSK-3
To verify that the accumulation of b-catenin in the DKO
cells was due to the lack of GSK-3 and not to some other
event that had occurred during the multiple manipulations
required to generate the DKO cells, we re-expressed WT
and mutant forms of GSK-3 by using stable transfection
Figure 3. Immunoblot Analysis of GSK-3-Gene Dosage
Effects on Wnt-Signaling Intermediates
(A) Examination of b-catenin phosphorylation in WT and DKO ESCs
treated 30 min with Wnt-3a-conditioned medium (CM).
(B) Levels of key Wnt-signaling molecules after long-term (20 hr) treat-
ment with Wnt-3a CM.pmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc. 961
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(A) Immunofluorescent images of DKO ESCs and DKO ESCs reconsti-
tuted with a GSK-3a-GFP fusion protein. b-catenin staining is red, GFP
staining is green, and nuclear staining is blue (DAPI).962 Developmental Cell 12, 957–971, June 2007 ª2007 Elsevierand lentiviral transduction. Reintroduction of WT GSK-3a
(Figure 4) or GSK-3b (data not shown), with or without epi-
tope or fluorescent protein tags, resulted in normalization
of cytosolic and nuclear b-catenin levels, as assessed by
immunofluorescence microscopy (Figures 4A and 4B).
True WT cells (Figure 4B) were indistinguishable from
DKO cells reconstituted with GSK-3a-GFP (Figure 4A) by
stable transfection or transduced with lentivirus express-
ing V5-epitope-tagged WT GSK-3a. A V5-tagged S21A
mutant of GSK-3a that cannot be inactivated through
phosphorylation of S21 reregulated b-catenin levels in
DKO ESCs to the same extent as V5-tagged WT GSK-
3a (Figure 4B). On the other hand, a kinase-dead
(K148A) GSK-3a mutant was ineffective in decreasing
b-catenin staining, confirming the role of the kinase activ-
ity of GSK-3 in the regulation of b-catenin levels. Tyrosine
phosphorylation of GSK-3 is required for full enzymatic
activity (Y216 of GSK-3b; Y279 of GSK-3a) (Doble and
Woodgett, 2003; Frame and Cohen, 2001). DKO cells
transduced with lentivirus expressing V5-GSK-3a with
a Y279F mutation only partially reduced cytosolic and
nuclear b-catenin with respect to WT levels (Figure 4B;
Figure S1). This finding is in agreement with the findings
of Hagen et al. (2002), who reported that the Y216Fmutant
of GSK-3b when overexpressed in HEK293 cells was
severely compromised in its ability to regulate b-catenin
levels and activity in these cells.
The mechanism by which GSK-3 phosphorylation of
b-catenin is reduced in the destruction complex upon
activation of Wnt signaling is still unclear. Although it
has been suggested that GSK-3 may be inactivated
through Wnt-induced serine 9/21 phosphorylation, there
are several lines of evidence that show that this is not
the case (Ding et al., 2000; McManus et al., 2005).
Most conclusively, mice in which both GSK-3a and
GSK-3b were genetically manipulated so that they ex-
pressed only S9A/S21A mutant alleles of GSK-3b and
GSK-3a, respectively, are viable, fertile, and grossly
normal (McManus et al., 2005). As expected, DKO cells
stably expressing the S21A mutant of GSK-3a, while
incapable of being phosphorylated at S21 by IGF-1 treat-
ment, were fully able to respond to Wnt-3a-conditioned
medium, as judged by an increase in cytosolic b-catenin
levels similar to those seen in WT cells (Figure 4C).
GSK-3a and GSK-3b Null ESCs Display
Differentiation Defects
A notable feature of the DKO ESCs that we observed
while generating them was that they retained an ideal,
(B) Immunofluorescent images of WT and DKO ESCs as well as DKO
ESCs rescued with various V5-epitope-tagged mutants of GSK-3a
through lentiviral transduction. V5 staining is green, b-catenin staining
is red, and nuclear staining is blue. All images were obtained with iden-
tical PMT, resolution, and scan-rate settings.
(C) DKO ESCs rescued with a GSK-3a S21A mutant still respond to
Wnt-3a. #9and#10are independent clonesofDKOESCs reconstituted
with S21A-GSK-3a. Treatments with IGF-1 were done for 15min, while
treatments with Wnt-3a-conditioned medium were done overnight.
The scale bars are 20 mm.Inc.
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DKO, Display a Limited Potential for
Differentiation
(A) Embryoid bodies derived from the same
number (800) of WT or DKO ESCs at various
time points after the initiation of differentiation.
The scale bar is 200 mm.
(B) Oct-4 immunfluorescence staining of WT
and DKO EBs differentiated for 14 days in the
absence of LIF. The scale bar is 50 mm.
(C) Nanog immmunofluorescence staining of
WT and DKO EBs differentiated for 12 days in
the absence of LIF. The scale bars are 20 mm.
(D) Semiquantitative RT-PCR analysis of WT
and DKO EBs at day 0 (d0) and day 7 (d7) of
differentiation.undifferentiated, highly refractile ESC-colony morphology
even under conditions whereWT ESCs started to differen-
tiate. Immunofluorescence images of DKO colonies when
compared to images of WT colonies revealed that the
DKO cells had amuch smaller cytoplasmic to nuclear ratio
and were more tightly packed in their colonies than WT
cells (Figure 4A). We therefore sought to determine
whether the DKO ESCs were impaired in their ability to
differentiate compared to WT ESCs.DeveloUsing the hanging-drop method, we created embryoid
bodies (EBs) fromWT or DKOESCs.WhileWT cells devel-
oped normally into EBs with transparent cystic structures
reminiscent of the embryonic yolk sac, over the course of
7–8 days in differentiation medium, the DKO cells never
formed these transparent cysts under identical conditions
(Figure 5A). More than 80% of the WT EBs (n > 200)
contained regions of spontaneously contracting cardio-
myocytes by day 8 of differentiation that were visiblepmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc. 963
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GSK-3 Regulation of Wnt SignalingFigure 6. Histological, Immunohistochemical, and PCR Examination of Teratomas Generated from ESCs either WT of Nullizygous
for GSK-3
(A) The WT teratomas possess numerous examples of glandular epithelial structures indicative of endoderm (the arrow indicates gut-like pseudos-
tratified epithelium).
(B) WT tumors also had large regions of neuronal tissue, indicating differentiation into ectoderm (the arrows point to neuronal nuclei).
(C and D) Differentiation of WT ESCs into mesoderm was confirmed by observation of (C) bone (the arrow points to a region of woven bone) and (D)
muscle (the inset shows magnification of striated skeletal muscle).964 Developmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc.
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contractile cells.
The extent of the defect in differentiation observed in the
DKO EBs was assessed by staining EBs for Nanog and
Oct-4, markers of pluripotent mouse ESCs (Chambers
et al., 2003; Rosner et al., 1990). Maintained for 14 days
in the absence of LIF and in 5% FBS, the DKO EBs, but
not the WT EBs, retained large numbers of Oct-4-positive
cells (Figure 5B). Furthermore, DKO EBs at day 12, still
contained detectable levels of Nanog, while the WT EBs
did not (Figure 5C). At the transcriptional level, oct-4,
nanog, and rex-1, another pluripotent ESC marker (Ben-
Shushan et al., 1998), were detectable after 7 days of
differentiation in DKO EBs, but transcripts of these genes
were present at much lower levels inWT EBs, as assessed
by semiquantitative RT-PCR analysis (Figure 5D). Quanti-
tative RT-PCR of oct-4, nanog, and rex-1 confirmed that
DKO, but not WT, EBs maintained high levels of ESC
marker gene transcripts after 7 days in the absence of
LIF and in reduced serum (5%FBS) conditions (Figure S3).
Surprisingly and interestingly, expression of brachyury/
transcription factor T, one of the earliest markers of meso-
derm differentiation (Herrmann et al., 1990), was upregu-
lated in the DKO cells even before withdrawal of LIF
(Figure 5D; Figure S3). Expression of axin2was also higher
in DKOEBs compared toWTEBs at the outset, and 7 days
after being cultured in differentiation medium. These data
confirmed that morphologically undifferentiated DKO
ESCs and ‘‘differentiated’’ DKO EBs both retain high tonic
levels of b-catenin/TCF-mediated transcription, and that
our data are in agreement with previous findings that
brachyury is a target of Wnt signaling (Arnold et al.,
2000; Yamaguchi et al., 1999). To address whether the
extremely high levels of brachyury transcript expression
(403 higher than WT levels; Figure S3) could be detected
at the protein level, we examined Brachyury by immuno-
blotting and immunofluorescence techniques. A band
running at the expected size (47 kDa) was detected by
immunoblotting with a Brachyury-specific antibody in
DKO lysates only (Figure S4A). Furthermore, DKO ESCs
displayed intense immunofluorescence staining for Bra-
chyury, including bright staining that colocalized with the
nuclear stain DAPI, whileWT cells hadmuchweaker stain-
ing, none of which appeared to be nuclear (Figure S4B).
Teratoma Analyses Confirm that DKO ESC
Differentiation Is Impaired
WT pluripotent ESCs, when injected into an immunocom-
promised or syngeneic mouse, form tumors known as
teratomas, which comprise all three germ layers (i.e.,Develoendoderm, ectoderm, and mesoderm) (Stevens, 1967).
We tested the ability of WT and DKO ESCs to form the
three germ layer lineages in teratomas generated in the
hind legs of syngeneic 129Ola mice. Sections of the tera-
tomas generated from WT ESCs had clear examples of
tissues of endo-, ecto-, and mesodermal origin (Figures
6A–6D). In contrast, all teratomas generated from DKO
ESCs had a grossly undifferentiated carcinomatous ap-
pearance, with the only differentiated structures observed
being spicules of bone (Figures 6E and 6F). Immunostain-
ing for b-catenin had the expected localization in WT
teratomas, and the strongest staining was apparent at
juxtaposed plasmamembranes of adjacent epithelial cells
where adherens junctions are located (Figure 6G). Only
weak cytoplasmic, and no nuclear, staining was observed
in WT epithelial cells. In marked contrast, b-catenin stain-
ing in DKO teratomas was very strong throughout the
teratoma mass, and membrane, cytoplasm, and nuclear
staining were observed in practically every cell of the
teratomas (Figure 6J).
Careful observation of numerous hematoxylin and
eosin-stained tissue sections from different DKO tera-
tomas generated in four separate animals revealed a
complete absence of neuronal tissue, in contrast to WT
teratoma sections, which contained many examples of
neuronal cell types. We sought to confirm this observation
by immunostaining for the neural progenitor marker Nestin
and the astrocyte marker glial fibrillary acidic protein
(GFAP). Nestin and GFAP stained strongly in regions of
the teratomas generated from WT ESCs (Figures 6H and
6I, respectively), while staining for these markers was
completely absent in DKO teratomas (Figures 6K and 6L).
The peculiar presence of bone in the largely undifferen-
tiated teratomas generated from DKO ESCs was substan-
tiated by RT-PCR analysis. The genes associated with
bone development/osteoblastogenesis, osterix, runx2,
osteocalcin, and alkaline phosphatase (Lian et al., 2006;
Salingcarnboriboon et al., 2006), were all found to be
expressed at higher levels in DKO teratomas than in WT
teratomas (Figure 6M). In addition, supporting the undif-
ferentiated nature of the DKO teratomas, expression of
nanog and oct-4 was also higher in DKO teratomas than
in those formed from WT ESCs. Quantitative assessment
of oct-4 and nanog expression revealed that DKO tera-
tomas still expressed oct-4 and nanog at relatively high
levels (28% and 14% of the levels found in WT ESCs
maintained in undifferentiated conditions, respectively;
Figure 6N). In contrast, WT teratomas had oct-4 and
nanog transcript levels that were an order of magnitude
lower than those in DKO teratomas, with both genes(E and F) DKO teratomas contain tightly packed cells in undifferentiated tissue reminiscent of a carcinoma with scattered spicules of bone (arrows).
(G) Immunohistochemical staining for b-catenin revealed normal membranous staining in epithelial cells of WT teratomas.
(H and I) Staining for the neuronal-progenitor marker Nestin and the astrocytic marker GFAP was clearly observed in WT teratomas.
(J) DKO teratomas displayed very high levels of b-catenin immunoreactivity in all cells in membrane, cytosol, and nuclear compartments.
(K and L) There was no detectable staining for Nestin or GFAP in DKO teratoma tissue sections.
(M) Semiquantitative RT-PCR analyses of WT versus DKO gene expression.
(N) Quantitative RT-PCR analyses of nanog and oct-4 transcript levels in WT ESCs (day 0) or teratomas generated from WT or DKO ESCs harvested
3 weeks after ESC injection. Error bars = SEM.
The scale bars are 100 mm.pmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc. 965
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GSK-3
(A) Immunoblot analyses of cytosolic lysates prepared from WT and DKO ESCs as well as DKO ESC cell lines stably expressing V5-tagged WT- or
K148A-GSK-3a.
(B) Semiquantitative RT-PCR analysis of transcripts expressed in the same cell lines examined in (A).
(C–N) Immunofluorescence images of EBs maintained for 14 days in LIF-free medium. EBs derived from (C and F) V5-WT-GSK-3a-expressing DKO
ESCs, (D and G) V5-K148A-GSK-3a-expressing DKO ESCs, and (E and H) DKO ESCs double stained for Oct-4 and GFAP, respectively. EBs derived
from (I and L)WT ESCs, (J andM) V5-WT-GSK-3a-expressing DKOESCs, and (K andN) V5-K148A-GSK-3a-expressing DKO ESCs stained for Nestin
and Nestin/DAPI (nuclear stain) merge, respectively.
The scale bars are 100 mm in all micrographs.expressed at 1%of the levels found in undifferentiatedWT
ESCs (Figure 6N). Together, our teratoma data strongly
suggest that DKO ESCs are significantly impaired in their
ability to differentiate properly, especially into neurecto-
dermal cell types, and that there is probably a population
of ES or ES-like cells that is maintained in the DKO tera-
toma masses.
DKO ESC Properties Can Be Completely Rescued
with a WT GSK-3a Transgene
We generated stable cell lines from DKO ESCs that stably
express equivalent levels of WT or kinase-dead (K148A)
GSK-3a with a V5-epitope tag located at the carboxy ter-966 Developmental Cell 12, 957–971, June 2007 ª2007 Elsevieminus. For long-term stable expression, we used the
human EF-1a promoter, since we found that our original
‘‘stable’’ lines with CMV promoter-driven GSK-3 (lines as-
sessed in Figure 4) lost their high expression levels within
a few cell passages. Immunoblot analysis confirmed that
the V5-tagged GSK-3a WT and K148A were expressed
at equivalent levels in the clones we chose for further anal-
ysis (Figure 7A). The level of transgenic GSK-3a in both the
WT- and kinase-dead-rescued clones was equivalent to
that produced by a single allele of GSK-3, based on
comparison with endogenous GSK-3a levels in WT cells
(Figure 7A). This level of WT GSK-3a-V5 protein was suffi-
cient to normalize cytosolic b-catenin levels to just slightlyr Inc.
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dead GSK-3a-V5 had no effect on b-catenin protein levels
(Figure 7A).
To further assess the rescue of DKO ESCs by expres-
sion of WT-GSK-3a, we examined the steady-state levels
of a panel of transcripts that we had observed to be differ-
entially expressed in WT and DKO ESCs. The transcripts
for axin2, brachyury, and cdx1 are all elevated in DKO
ESCs when compared with WT ESCs maintained in stan-
dard ESC culture conditions with LIF supplementation
(Figure 7B). The ESC-associated genes nanog and oct-4
are both expressed at high levels in both WT and DKO
ESCs (Figure 7B). The expression profile of DKO ESCs
was changed to that of WT ESCs upon stable expression
of GSK-3a-V5, but it was unchangedwith the kinase-dead
transgene (Figure 7B). Thus, re-expressionofWT-GSK-a in
DKO ESCs is sufficient to ‘‘reprogram’’ the cells at the
level of transcription.
We used WT and kinase-dead GSK-3a-expressing
DKO ESCs, as well as WT and DKO ESCs, to form EBs
by using the hanging-drop method to assess their differ-
entiative capacities. An obvious difference between EBs
formed from DKO ESCs and WT-GSK-3a-V5-rescued
DKO ESCs was that while DKO ESCs never gave rise to
spontaneously contracting cardiomyocytes in their EBs,
some of the WT-rescued EBs did (16 of 76 EBs scored
at day 7 of differentiation). As we observed with EBs
derived from WT ESCs (Figure 5B), EBs resulting from
aggregation of DKO ESCs expressing WT-GSK-3a-V5
had no detectable Oct-4 through immunofluorescent visu-
alization (Figure 7C). In contrast, DKO EBs expressing
kinase-dead GSK-3a-V5 still contained clusters of cells
expressing Oct-4 (Figure 7D) at the same frequency as
DKO EBs (Figure 7E). To confirm that the rescued DKO
ESCs regained their ability to differentiate into neurecto-
derm upon stable expression of GSK-3a, we tested the
ability of GSK-3a-V5 transgene-expressing DKO ESCs
to form EBs that stained positively for GFAP and Nestin.
Very strong GFAP staining was observed in EBs express-
ing WT-GSK-3a-V5 (Figure 7F), while only weak back-
ground staining was seen in EBs expressing kinase-
dead GSK-3a-V5 or no GSK-3 (DKO) (Figures 7G and
7H, respectively). Similarly, WT and WT-rescued DKO
ESCs formed EBs that stained strongly for Nestin (Figures
7I/7L and 7J/7M, respectively), while kinase-dead GSK-
3a-rescued DKOs formed EBs that were devoid of Nestin
staining (Figures 7K and 7N). Together, our rescue data
suggest that re-expression of active GSK-3 in DKO
ESCs is sufficient to revert them to a WT ESC identity in
all respects.
DISCUSSION
Our data provide conclusive evidence, for the first time to
our knowledge, that both mammalian GSK-3 homologs
function identically in Wnt signaling. This redundancy in
function has not been appreciated in the Wnt-signaling
field, where the role of GSK-3b has been overemphasized.
Historically, this bias most likely arose from reports sug-Develogesting a difference in the efficacy of rescue of the zeste-
white3 (GSK-3) mutation in Drosophila by mammalian
GSK-3a and GSK-3b, in which the b isoform appeared
to be more effective than the a isoform (Ruel et al., 1993;
Siegfried et al., 1992). However, in these studies, the
amount of expression of the two homologs was not equal-
ized. Our genetically manipulated ESCs allowed us to
demonstrate that either GSK-3 homolog is necessary
and sufficient to regulateWnt/b-catenin signaling in ESCs.
Our data also clearly show that there is no compensa-
tory upregulation of GSK-3 protein levels or kinase activity
in the knockout cell lines. It should be noted that our
kinase assays, which used a glycogen synthase phos-
phopeptide substrate known as GS-2, revealed ‘‘back-
ground’’ kinase activity in our DKO ESCs. It has been
shown previously that while GS-2 is largely specific for
phosphorylation by GSK-3, it can also be phosphorylated
by other kinases (Kuma et al., 2004; Skurat and Dietrich,
2004).
We observed a clear and tonic upregulation of
b-catenin/TCF-mediated signaling, as assessed by obser-
vation of b-catenin levels, TCF-reporter activity, and upre-
gulation of axin2, cdx1, and brachyury, which are known
examples of TCF-responsive genes. While we were sur-
prised to see that the morphologically undifferentiated
DKO ESCs expressed high levels of brachyury at both
the RNA and protein levels, the existence of a population
of undifferentiated colonies of mESCs that are positive
for both Nanog and Oct-4 and also for Brachyury has
recently been reported and has been termed ‘‘early meso-
derm-specified (EM) progenitors’’(Suzuki et al., 2006). The
only difference between EM progenitors and ESCs is
expression of Brachyury. Modulation of LIF concentra-
tions in the culture medium can cause exchange of EM
progenitor and ESC identities. That is, EM progenitors
can revert to ESCs. Thus, it is possible that the GSK-3
null DKO cells described here that appear to be ESCs by
morphological criteria are actually more closely related
to EM progenitors.
The gene encoding the homeobox-containing tran-
scription factor Cdx1 has been shown to be upregulated
by Wnt-3a in ESCs and has been suggested to be a direct
Wnt-target gene (Lickert et al., 2000). The high levels of
cdx1 gene expression in our DKO ESCs support this
notion. cdx1 is normally not expressed until embryonic
day 7.5 in the mouse, at which point it plays a role in the
development of the posterior embryo (Lohnes, 2003).
Our observation that DKO ESCs do not differentiate into
cardiac myocytes in our EB assay is in agreement with the
current paradigm of cardiac development that maintains
that the inhibition of canonical Wnt signaling is an absolute
requirement for cardiac myocyte specification (reviewed
in Eisenberg and Eisenberg, 2006). Thus, we can consider
our lack of cardiomyocytes in DKO EBs as a positive read-
out of hyperactivated Wnt signaling. Likewise, our obser-
vation that DKO EBs and teratomas lacked neuronal
tissue is supported by other studies that have found that
Wnt signaling activated in ESCs through GSK-3 inhibitors,
stabilized b-catenin, mutant APC, or Wnt treatmentpmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc. 967
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Haegele et al., 2003; Kielman et al., 2002). Taken together,
it appears that while GSK-3 is known to play a role in
numerous pathways, the dominant effect of GSK-3 abla-
tion in ESCs appears to be related to its effects on Wnt
signaling. A more detailed analysis of the differentiative
capacity of the DKO ESCs will be necessary to determine
if any non-Wnt-specific functions of GSK-3 play a role in
ESC differentiation.
The presence of bone in teratomas derived from DKO
ESCs was somewhat surprising, since we were expecting
a similar phenotype to APC(min/min) mutant ESCs, which,
like our DKO cells, have highly deregulated Wnt signaling
due to the inability of the min mutant of APC to bind b-cat-
enin (Kielman et al., 2002). ESCs derived from APC(min/min)
blastocysts are incapable of forming teratomas in synge-
neic mice. The bone phenotype we see in DKO teratomas
is most likely due to activated Wnt signaling, as there is
extensive evidence linking Wnt signaling to osteoblasto-
genesis (Lian et al., 2006). The mechanism underlying
the incredible specificity of the differentiation of DKO
ESCs in teratomas is unclear. The bone-specific differen-
tiationmay require extrinsic factors provided by themicro-
environment of the teratomas since high levels of osteo-
genic transcription factors were not observed in 14-day
EBs generated from DKO ESCs (data not shown).
The enhanced retention of ESC markers that we ob-
serve in the DKO ESCs under differentiation conditions
(teratomas and EB assays) is consistent with the report
of Sato et al. (2004) that suggested that Wnt signaling or
GSK-3 inhibition could maintain pluripotency of mouse
and human ESCs. Their data, in part, focused on the ef-
fects of the GSK-3-inhibitor BIO. This inhibitor, as with
any small-molecule inhibitor, is subject to potential ‘‘off-
target’’ effects. To our knowledge, our data are the first
to confirm that genetic inactivation of GSK-3 is sufficient
to severely compromise ESC differentiation. Our data
are also consistent with the findings of Kielman et al.
(2002), who found that mESCs containing different
mutants of APC, with increasing levels of b-catenin and
TCF activity, becamemore restricted in their developmen-
tal capacity.
The mechanism through which GSK-3 influences ESC
differentiation is, at least in part, due to its function in
Wnt signaling, although we cannot exclude its role in other
pathways. For example, the PI-3K pathway, which is
known to negatively regulate GSK-3 through serine phos-
phorylation of its amino-terminal domain, has been shown
recently to play a role in the maintenance of mouse and
primate ESC pluripotency (Paling et al., 2004; Storm
et al., 2007; Watanabe et al., 2006). Also, GSK-3 phos-
phorylation of Myc on T58 has been implicated in the
LIF/STAT3-mediated regulation of mouse ESC pluripo-
tency, since overexpression of a T58A mutant of Myc in
mouse ESCs promotes their self-renewal and pluripo-
tency in the absence of exogenous LIF (Cartwright et al.,
2005). Indeed, we have found that our DKO ESCs do not
have detectable levels of Myc phosphorylated on T58
(data not shown). Still, only a subpopulation of cells within968 Developmental Cell 12, 957–971, June 2007 ª2007 Elsevie‘‘differentiated’’ DKO EBs express the pluriopotency
markers Nanog and Oct-4. This suggests that, even in
the presence of stabilized b-catenin and Myc, other fac-
tors, perhaps related to cell polarity or local environment,
are required for maintenance of the true pluripotent state.
Conclusions
Taken together, our findings provide important new, to our
knowledge, insights into the mode of substrate regulation
by GSK-3. GSK-3 serves as a regulatory component in
numerous signaling pathways. The rationale for the exis-
tence of two GSK-3 isoforms encoded by distinct genes
is unclear. From our studies focusing on the canonical
Wnt pathway, it appears that there is a very high level of
functional redundancy with respect to GSK-3 homologs.
We anticipate that this redundancy in function will exist
in many, if not all, of the pathways that require GSK-3.
We demonstrate that GSK-3a and GSK-3b are equally ca-
pable of maintaining low levels of b-catenin, and that only
upon inactivation of three of the four alleles, or complete
loss of all four, is there any discernable impact on Wnt-
signaling proteins and b-catenin levels. This is of clinical
relevance in conditions in which elevated GSK-3 activity
is deleterious, such as Alzheimer’s disease and Type II
diabetes. There are no data suggesting that the pool of
GSK-3 deregulated in these diseases is the Axin-bound
GSK-3 reserved for canonical Wnt signaling. Our data
suggest that there may be a therapeutic window and
dose for GSK-3 inhibitors in treating diseases without
elevating b-catenin levels and thus a risk of oncogenic
events. Our findings with respect to ESC differentiation
suggest that pathways regulated by GSK-3, at least the
Wnt pathway, are critically involved in the maintenance
of ESC identity. The GSK-3-less DKO cells could serve
as an important tool for the dissection of LIF-independent
pathways responsible for the maintenance of ESC identity
and self-renewal in mouse and human ESCs.
EXPERIMENTAL PROCEDURES
Plasmids
A clone containing the full-length cDNA for murine GSK-3a was pur-
chased from Open Biosystems (IMAGE clone 4011973). QuikChange
(Stratagene) was used to generate the following mutants of GSK-3a,
each with a single amino acid substitution: S21A, K148A, and
Y279F. A mammalian expression plasmid containing a single FRT re-
combination site was created by splicing the CMV promoter, multiple
cloning site, polyA signal, and puromycin-resistance cassette from
pPUR (Clontech) into the BspEI and Bst11071 sites of pcDNA5/FRT
(Invitrogen) to yield pcDNA5/FRT_puro. WT and mutant versions of
GSK-3a were subcloned into the KpnI and ApaI sites of this vector.
Where necessary, appropriate restriction-enzyme sites were added
to the termini of PCR primers prior to ligations. To generate GFP-
GSK-3a fusions, an NdeI/KpnI fragment containing part of the CMV
promoter and the EGFP-coding sequence from pEGFP-C1 (Clontech)
was cloned into NdeI/KpnI-cleaved pcDNA5/FRT_puro_GSK-3a.
Stable cell lines expressing V5-tagged GSK-3 fusion proteins were
produced by cloning PCR-amplified GSK-3 variants into pEF5/FRT/
V5 directional TOPO by following the manufacturer’s instructions
(Invitrogen).
For in vitro Cre- and FLPe-mediated excisions, pIC-Cre (Gu et al.,
1993) and pCAGGS-FLPe (GeneBridges, Germany), respectively,r Inc.
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XFOPFlash (Veeman et al., 2003) (obtained from Randall Moon,
University of Washington) were used in conjunction with pRL-CMV
(Promega).
Cell Culture/Embryoid Body Assay
All media and supplements were obtained from GIBCO-BRL (Invitro-
gen) unless otherwise noted. ESCs (E14K) were maintained in Knock-
out DMEM supplemented with 15% FBS (Hyclone), 13 nonessential
amino acids, 13 GlutaMax-I, 13 2-mercaptoethanol, and 1000 U/ml
ESGRO (Chemicon). Differentiation medium for the production of em-
byroid bodies was ESC maintenance medium with the serum content
reduced to 5% and no ESGRO supplementation. EBs were propa-
gated in hanging drops on 10 cm2 bacterial dishes (800 single ESCs/
30 ml drop initially) for 3 days and were then transferred to ultra-low-
binding 96-well dishes (Corning) and cultured with differentiation
medium that was replenished every 2 days.
L-cells stably expressing Wnt-3a and control WT L cells were
obtained from the ATCC, and conditioned medium was prepared
according to the protocol provided with the cells.
Semiquantitative RT-PCR
Total RNA was isolated by using QIAGEN’s RNeasy kit. Reverse tran-
scription was carried out by using SuperScriptII (Invitrogen). The tem-
plate for each PCR reaction was the cDNA obtained from 50 ng total
RNA. The number of PCR cycles for b-actin and GAPDH was 25, while
all other targets were examined after 30 cycles of amplification. Primer
sequences are listed in Table S1.
Quantitative RT-PCR
RNA isolation and reverse transcription were carried out as described
for semiquantitative RT-PCR. The template for each PCR reaction was
the cDNA obtained from 25 ng total RNA in a 25 ml reaction volume.
Primers were designed by using the online PrimerQuest software pro-
vided by IDT, the company that synthesized the primers for us. Plati-
num SYBR green qPCR SuperMix-UDG (Invitrogen) was used accord-
ing to the manufacturer’s recommendations for the Stratagene
Mx3000P real-time PCR machine, which was used for all real-time
experiments. The software package MxPro (Stratagene) was used to
calculate the relative differences in gene-expression levels, by using
the delta-delta Ct method, with b-actin used as the housekeeping
gene for normalization of samples. The sequences of the primers
used for qPCR analyses are provided in Table S2.
Cytosolic Lysate Preparation
Cytosolic lysates were prepared by rinsing cells three times with PBS,
then scraping them into a minimal volume of ice-cold hypotonic lysis
buffer (50 mM Tris [pH 7.4], 1 mM EDTA) containing a cocktail of pro-
tease and phosphatase inhibitors (Complete protease inhibitor tablet
(Roche), phosphatase inhibitor cocktail 1 [P2850 Sigma]; 1 mM Na-
orthovanadate, 10 mM NaF, 10 mM b-glycerophosphate). Cells were
pelleted by centrifuging for 1 hr at maximum speed in a bench-top
microfuge at 4C. Cytoplasm expelled from the cells was retrieved
by collecting the supernatant, taking care not to aspirate any insoluble
material located in the pellet or floating on the surface of the lysate. In-
soluble proteins in the pellets from hypotonic lysates were extracted
with 2% SDS, 50 mM Tris (pH 6.8), containing protease and phospha-
tase inhibitors.
GSK-3 Kinase Assay
ESCs from a confluent T175 flask were harvested by using 2 ml deter-
gent-free lysis buffer (50 mM Tris-HCl, 4 mM EDTA, 2 mM EGTA,
10 mM Nab-glycerophosphate, 25 mM NaF, 1 mM PMSF, 1 mM Na-
orthovanadate, protease, and phosphatase inhibitor cocktail [pH
7.5]) and homogenized in a 1 ml Dounce homogenizer with 10 strokes
of pestle A and B. The lysates were centrifuged at 14,000 3 g for 30
min, and the supernatant was applied to a pre-equilibrated (25 mM
Tris-HCl, 2 mM EDTA, 1 mM EGTA, 10 mM Nab-glycerophosphate,Develo5% glycerol, 25 mM NaF, 1 mM PMSF, 1 mM Na-orthovanadate, pro-
tease, and phosphatase inhibitor cocktail [pH 7.5]; buffer A) CM-
Sepharose fast-flow resin (Amersham). The column was washed with
five column volumes of low-salt wash buffer (buffer A + 25 mM
NaCl), and GSK-3 was eluted with elution buffer (buffer A + 200 mM
NaCl). Fractions containing the highest concentrations of protein
were pooled and used in a kinase assay to assess GSK-3 activity.
GSK-3 kinase assays were performed with an equivalent amount of
eluted protein at 30C for 15 min in a 50 ml reaction volume containing
8 mM MOPS (pH 7.4), 0.2 mM EDTA, 15 mM MgCl2, 0.1 mM EGTA,
2.5 mMprotein kinase A inhibitor (PKI, Upstate Biotech), 10mMmagne-
siumacetate, 5mMNa b-glycerophosphate, 25 mMglycogen synthase
2 peptide (Upstate Biotech) and initiated with 2 mCi/ml [g-32P]ATP (6000
Ci/mmol). A total of 40 ml of the reaction mixture was spotted onto
2 cm2 squares of Whatman phosphocellulose P81 paper that was
washed five times with 0.75%phosphoric acid and once with acetone;
the incorporation of radioactivity in the peptide was determined by
using a Beckman LS 6500 liquid scintillation counter. As the ratio of
GSK-3a:GSK-3b was altered in the partial purification compared to
whole-cell lysate (in which it is 1:1), activities were corrected for the
partial-purification loss of GSK-3a, as determined by immunoblotting
of the assayed fractions. The relative activities are an average of six
assays from two independent experiments in which each kinase assay
was performed in triplicate.
Antibodies
All phospho-specific antibodies were purchased from Cell Signaling
Technologies: anti-phospho-b-catenin, S33/S37/T41 (#9561: Lot1)
and S45/41 (#9565); anti-phospho-GSK-3, S9/S21 (#9331); and anti-
phospho-PKB, S473 (#4058). Other antibodies used were anti-b-actin,
ab6276 (Abcam); anti-APC, sc-895 (Santa Cruz); anti-Brachyury, sc-
17743 (Santa Cruz); anti-b-catenin, clone 14 (BD Biosciences); anti-
Conductin, sc-20784 (Santa Cruz); anti-GAPDH, ab8245 (Abcam);
anti-GFAP, Z0334 (DAKO); anti-GSK-3, clone 4G-1E (Upstate); anti-
Nanog, ab21603 (Abcam); anti-Nestin, MAB353 (Chemicon); and
anti-Oct-4, sc-9081 (Santa Cruz). Species-specific antibodies conju-
gated to Alexa Fluors 488 and 594 were obtained from Molecular
Probes.
Immunofluorescence Microscopy
Cells/EBs were fixed with 4% paraformaldehyde/PBS for 15 min at
room temperature and permeabilized with 0.1% Triton X-100/PBS at
room temperature for 2 min (cells) or 15 min (EBs). EBs were freeze-
fractured before fixation and permeabilization by sandwiching them
between positively charged slides (Fisher Scientific), freezing for
10 min on dry ice, and then quickly prying apart the slides to fracture
the EBs (modification of protocol of Toumadje et al. [2003]). Primary
and secondary antibodies were diluted to final working concentrations
in 2% BSA/PBS. Specimens were mounted with ProLong gold anti-
fade reagent containing DAPI (Molecular Probes). Images of immuno-
fluorescent samples were obtained with a Zeiss LSM510 confocal
microscope.
Immunohistological Staining of Teratomas
Sections from paraffin-embedded teratomas were dewaxed and
rehydrated by following standard procedures. Antigen retrieval for
b-catenin and Nestin was achieved by using heat-induced retrieval
in citrate buffer (pH 6.0), while proteolytic antigen retrieval with protein-
ase K (DAKO) was used for GFAP. The following primary antibody
concentrations were used: anti-b-catenin, 1:250; anti-GFAP, 1:500;
anti-Nestin, 1:200. Kits specific for rabbit or mouse antigen detection
in mouse tissues (Vector Labs and DAKO, respectively) were used
according to the manufacturers’ recommendations.
Transient Transfections
Single-cell suspensions of ESCs were transfected with Lipofectamine
2000 (Invitrogen) by using 1–2 million cells, 2 mg DNA, and 4 mlpmental Cell 12, 957–971, June 2007 ª2007 Elsevier Inc. 969
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coated, 6-well plate (Bugeon et al., 2000).
TCF-Reporter Assay
ESCs were cotransfected with TCF-reporter constructs (1.8 mg), driv-
ing firefly luciferase production, and a pRL-CMV (0.2 mg), driving con-
stitutive expression of renilla luciferase for normalization. Treatments
withWnt-3a-conditioned medium were done the day after transfection
with reporter constructs, and cells were lysed with 13 passive reporter
lysis buffer. Firefly and renilla reporter activities were measured by
using a 96-well-based luminometer and were detected as per manu-
facturer’s instructions (Promega Dual-Light system).
Lentivirus Production
WT and mutant versions of GSK-3a were cloned into the pLenti6/V5
directional TOPO vector, and lentiviruses were produced according
to the instructions provided by the manufacturer of the ViraPower
lentiviral expression system (Invitrogen).
Teratoma Production
GSK-3a(flx/flx) and DKO ESCs grown for two passages on gelatin-
coated dishes to eliminate feeder fibroblasts were trypsinized into
single-cell suspensions and resuspended in PBS to a concentration of
107 cells/ml. These cells were injected subcutaneously into the hind
limbs of syngeneic 129Ola mice (Harlan) by using a 25 Ga needle
(200 ml). Teratomas were collected after 3 weeks. Small samples
were collected for RNA isolation, and the remainder of the tissue
was fixed with neutral-buffered formalin overnight at 4C for subse-
quent paraffin embedding, sectioning, and histological/immunohisto-
logical staining.
Statistical Analyses
All statistical analyses were performed by using the GraphPad Prism
software package. The TCF-reporter assay data were analyzed by
ANOVA with the Newman-Keuls post-hoc test. There were four repli-
cate samples for each treatment group. The quantitation of the relative
amounts of GSK-3 in the various cell lines was analyzed by ANOVA
with Tukey’s post-hoc test. The immunoblot-band profiles from three
independent cell lysates per cell type were used in the analyses.
Supplemental Data
Supplemental Data include sequences of PCR primers used in this
study and additional figures comparing the levels of GSK-3 and down-
stream effectors and are available at http://www.developmentalcell.
com/cgi/content/full/12/6/957/DC1/.
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